Ascendis Pharma A/S
NASDAQ:ASND
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
90.62
159.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
ASND Price Targets Summary
Ascendis Pharma A/S
According to Wall Street analysts, the average 1-year price target for ASND is 196.93 USD with a low forecast of 154.53 USD and a high forecast of 303.45 USD.
ASND Last Price Targets
Ascendis Pharma A/S
The latest public price target was made on Sep 23, 2024 by Tazeen Ahmad from Bank of America Securities , who expects ASND stock to rise by 49% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.
Analyst | Price Target | Date | Article |
---|---|---|---|
Tazeen Ahmad
Bank of America Securities
|
191
USD
Upside 49% |
1 month ago
Sep 23, 2024
|
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
StreetInsider
|
Leland Gershell
Oppenheimer
|
190
USD
Upside 48% |
2 months ago
Sep 17, 2024
|
Ascendis Pharma (ASND) PT Raised to $190 at Oppenheimer
StreetInsider
|
Derek Archila
Wells Fargo
|
289
USD
Upside 126% |
2 months ago
Sep 17, 2024
|
Ascendis Pharma price target raised to $289 from $264 at Wells Fargo
TheFly
|
Gavin Clark-Gartner
Evercore ISI
|
205
USD
Upside 60% |
2 months ago
Sep 17, 2024
|
Ascendis Pharma price target raised to $205 from $191 at Evercore ISI
TheFly
|
David Lebowitz
Citigroup
|
207
USD
Upside 62% |
2 months ago
Sep 17, 2024
|
Ascendis Pharma price target raised to $207 from $178 at Citi
TheFly
|
Paul Choi
Goldman Sachs
|
200
USD
Upside 56% |
2 months ago
Sep 16, 2024
|
Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
StreetInsider
|
Tazeen Ahmad
Bank of America Securities
|
175
USD
Upside 37% |
2 months ago
Sep 16, 2024
|
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175
StreetInsider
|
David Lebowitz
Citigroup
|
178
USD
Upside 39% |
2 months ago
Sep 13, 2024
|
Citi Reiterates Buy Rating on Ascendis Pharma (ASND)
StreetInsider
|
Leland Gershell
Oppenheimer
|
180
USD
Upside 41% |
2 months ago
Sep 5, 2024
|
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
StreetInsider
|
Kelly Shi
Jefferies
|
196
USD
Upside 53% |
3 months ago
Aug 13, 2024
|
Ascendis Pharma price target raised to $196 from $174 at Jefferies
TheFly
|
Alex Thompson
Stifel Nicolaus
|
200
USD
Upside 56% |
5 months ago
May 30, 2024
|
Stifel Starts Ascendis Pharma (ASND) at Buy
StreetInsider
|
Vikram Purohit
Morgan Stanley
|
140
USD
Upside 9% |
6 months ago
May 15, 2024
|
Ascendis Pharma (ASND) PT Raised to $140 at Morgan Stanley
StreetInsider
|
Josh Schimmer
Evercore ISI
|
191
USD
Upside 49% |
8 months ago
Mar 14, 2024
|
Ascendis Pharma (ASND) PT Raised to $191 at Evercore ISI
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ASND's stock price target?
Price Target
196.93
USD
According to Wall Street analysts, the average 1-year price target for ASND is 196.93 USD with a low forecast of 154.53 USD and a high forecast of 303.45 USD.
What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
58%
For the last 8 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 55%. The projected CAGR for the next 3 years is 58%.